Telum Therapeutics
Telum Therapeutics uses synthetic biology and AI to develop engineered phage lytic proteins against difficult-to-treat infections.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
EquiLibre, Telum Therapeutics, Digiclean — AI trading, enzybiotics and cleaner factories — Daily News July 1, 2026
Listen to the episodeAbout Telum Therapeutics
Telum Therapeutics is a Spanish biotech focused on new antimicrobial therapies. Its APEXp platform uses synthetic biology and artificial intelligence to engineer phage lytic enzymes, aiming to create next-generation enzybiotics against multidrug-resistant bacteria. In July 2026 it raised an €18M Series A to advance its lead programme targeting Acinetobacter baumannii HABP/VABP through Phase 1.
The Story
Founded in 2019, Telum was created to turn synthetic biology and AI technology into antimicrobial therapies against resistant infections.
How Telum Therapeutics works
Business Model
Biotech drug development with potential monetisation through pharma partnerships, licensing, milestones and future commercialisation.
Revenue Model
Not disclosed; expected model based on clinical development, partnerships, licensing and milestones.
Products & Services
Key Products
- APEXp platform
- Lead programme for Acinetobacter baumannii HABP/VABP
Core Use Cases
- Hospital-acquired bacterial pneumonia
- Ventilator-associated bacterial pneumonia
- Multidrug-resistant Gram-negative infections
- Antimicrobial resistance
- Enzybiotic drug development
Market & Clients
Key Customers
Potential hospital patients, healthcare systems and pharma partners; product still in clinical development.
Geographic Presence
How Telum Therapeutics competes
Competitors
Competitive Advantages
- APEXp platform under patent and trade-secret protection
- Synthetic biology and AI-driven enzyme engineering
- Focus on high-need AMR indications
- Specialised AMR investor backing
How Telum Therapeutics grows
Growth Strategy
Complete Phase 1 for the lead programme and advance pipeline assets against Gram-negative and Gram-positive pathogens.
Distribution Model
Biotech clinical development with potential pharma partnerships and licensing.
Moat (Defensibility)
Proprietary APEXp platform, IP, phage lytic enzyme know-how, clinical programmes and specialised capital.
Regulatory Context
Development subject to clinical trials and pharmaceutical regulatory approvals; relevant to AMR health policy.
Key Risks
- Clinical risk
- Regulatory risk
- AMR commercial model complexity
- Manufacturing and stability of biologic/enzyme therapies
- Need for follow-on capital
Strategic Insights
- Antimicrobials require specialised capital and investors focused on AMR.
- The combination of synthetic biology and AI may accelerate therapeutic enzyme engineering.
- Moving the lead programme through Phase 1 changes the company's risk profile.
Funding & Investors
Funding Rounds
- 2026 - Series A: €18M
Lead: AMR Action Fund
Key Investors
Founding Team
Key Executives
- Dr. Subhendu Basu - Chief Executive Officer
Key Metrics
Lessons from Telum Therapeutics
- In biotech, platform value must be tied to a concrete clinical indication.
- In areas such as AMR, mission-driven investors can be crucial.
- Communication must distinguish scientific potential from clinical data still to be generated.
Similar Startups
Idoven 1903 SL
AI-powered cardiology platform that revolutionises ECG interpretation, enabling early detection of heart conditions and improving diagnostic precision.
Read AnalysisIntegra Therapeutics
Integra Therapeutics uses FiCAT — a fusion of Cas9 and engineered piggyBac transposase — to insert large therapeutic genes with high precision and without the payload size limitation typical of classical CRISPR, with applications in genetic diseases, oncology and autoimmunity.
Read AnalysisPragmatech
Pragmatech has developed an AI platform for dermatological image analysis that assists physicians in recognising suspicious skin lesions for early detection of melanoma and other skin cancers.
Read Analysis